Compare DFDV & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DFDV | VRCA |
|---|---|---|
| Founded | 2018 | 2013 |
| Country | United States | United States |
| Employees | 16 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.1M | 137.3M |
| IPO Year | N/A | 2018 |
| Metric | DFDV | VRCA |
|---|---|---|
| Price | $4.68 | $7.54 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $45.00 | $17.00 |
| AVG Volume (30 Days) | ★ 782.7K | 89.5K |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,577,000.00 |
| Revenue This Year | $32.58 | N/A |
| Revenue Next Year | $23.65 | $94.44 |
| P/E Ratio | $0.90 | ★ N/A |
| Revenue Growth | N/A | ★ 370.22 |
| 52 Week Low | $2.96 | $0.49 |
| 52 Week High | $53.88 | $9.82 |
| Indicator | DFDV | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 55.43 | 58.94 |
| Support Level | $3.11 | $7.24 |
| Resistance Level | $5.16 | $7.51 |
| Average True Range (ATR) | 0.36 | 0.66 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 63.52 | 57.45 |
DeFi Development Corp is a U.S. company committed to building its treasury around Solana (SOL), a fast-growing blockchain infrastructure platform. This equity delivers shareholders tangible exposure to SOL price movement and staking rewards, making the firm a proxy for the Solana ecosystem. The treasury extends to running its own validator infrastructure, allowing DFDV to actively participate in and benefit from the Solana network expansion. The firm has two segments: Digital Asset Treasury ("Treasury") and Real Estate Platform ("Real Estate"). The company generates the majority of its revenue from the Treasury segment.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.